Stock analysts at StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) in a report issued on Thursday. The firm set a “sell” rating on the stock.
Ayala Pharmaceuticals Price Performance
Shares of ADXS stock opened at $0.25 on Thursday. The stock has a market capitalization of $2.69 million, a PE ratio of -0.03 and a beta of 1.45. The business’s 50 day simple moving average is $0.36 and its 200 day simple moving average is $0.58. Ayala Pharmaceuticals has a one year low of $0.14 and a one year high of $1.95.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last posted its quarterly earnings data on Tuesday, April 16th. The company reported ($2.96) EPS for the quarter.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Read More
- Five stocks we like better than Ayala Pharmaceuticals
- How to Use the MarketBeat Dividend Calculator
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- Low PE Growth Stocks: Unlocking Investment Opportunities
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- 3 Healthcare Dividend Stocks to Buy
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
